Who founded Mid-Atlantic BioTherapeutics?

Mid-Atlantic BioTherapeutics was founded by Dave Jobes, Jean Pierre Gagnon.

How much funding has Mid-Atlantic BioTherapeutics raised?

Mid-Atlantic BioTherapeutics has disclosed $875K raised across 1 of its 3 known rounds.

Where is Mid-Atlantic BioTherapeutics headquartered?

Mid-Atlantic BioTherapeutics is headquartered in Doylestown, US.

Mid-Atlantic BioTherapeutics

Doylestown, US · Delaware corporation · 1 known investors

Find your way into Mid-Atlantic BioTherapeutics

253 people in our graph share verified history with the Mid-Atlantic BioTherapeutics team — schools, employers, funds. One of them is your warm intro.

Bianca Martinelliunlockedknows Jean Pierre Gagnon · together at Thunderbird School of Global Management (overlapped)

knows the team · via Thunderbird School of Global Management

×10knows the team · via University of Pennsylvania

A biotech company focused on infectious diseases, drawing on clinical and pharmaceutical development expertise across areas such as fungal diseases, bacterial infections, and vaccines. The company is led by physicians and scientists with backgrounds in infectious disease research, clinical development, and commercialization.

Biotech Healthtech

Founders & leadership

Dave JobesPresident & Co-Founder

Jean Pierre Gagnon Senior VP of Operations & Co-FounderCo-founder and Senior VP of Operations at Mid-Atlantic BioTherapeutics, a biotech company developing treatments for infectious diseases including fungal and bacterial infections and vaccines. Gagnon has over 35 years of experience in business operations, commercial strategy, and team leadership in corporate, biotech, and academic settings.

David HornCEO & Founder

Board

Julian ChickBoard director

Michael GoldblattBoard director

Andrew KatzBoard director

Investors · 1

Also in the syndicate · 1

Legend Innovation Life Science Fund

Reported raises · per SEC filings

Form D private placements

$875K disclosed across 1 of 3 rounds · 2018–2025

▶$5MofferedSep 2024 · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Julian ChickDirector
David HornExecutive Officer, Director
Michael GoldblattDirector
Andrew KatzDirector
David JobesExecutive Officer, Director
Jean Pierre GagnonDirector

Offering amount: $5M
Minimum investment: $50K
Sales commissions: $500K
Proceeds to insiders: $750K
Incorporated: Corporation, Delaware
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

▶$875KraisedOct 2018 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Jean Pierre GagnonExecutive Officer, Director
David HornExecutive Officer, Director
David JobesExecutive Officer, Director

Offering amount: $10M
Amount sold: $875K
Minimum investment: $25K
Proceeds to insiders: $250K
First sale: Jun 2018
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap

Aro Biotherapeutics8 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

Northwest Biotherapeutics7 shared keywordsNW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.

Mission BioCapital Platinum Program Holdings LLC6 shared keywordsMission BioCapital is a venture capital firm that invests in early-stage life science companies, from therapeutics and drug discovery to biotech tools and diagnostics. The firm provides capital, operational support, and lab infrastructure through its MBC BioLabs co-working spaces to help scientific entrepreneurs launch and scale biotech startups.

Maze Therapeutics5 shared keywordsMaze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization. Its pipeline focuses on kidney disease, including programs for APOL1-mediated kidney disease, chronic kidney disease, and phenylketonuria.

Bioworld5 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Mid-Atlantic BioTherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Mid-Atlantic BioTherapeutics do?: A biotech company focused on infectious diseases, drawing on clinical and pharmaceutical development expertise across areas such as fungal diseases, bacterial infections, and vaccines. The company is led by physicians and scientists with backgrounds in infectious disease research, clinical development, and commercialization.
Who founded Mid-Atlantic BioTherapeutics?: Mid-Atlantic BioTherapeutics was founded by Dave Jobes, Jean Pierre Gagnon.
How much funding has Mid-Atlantic BioTherapeutics raised?: Mid-Atlantic BioTherapeutics has disclosed $875K raised across 1 of its 3 known rounds.
Where is Mid-Atlantic BioTherapeutics headquartered?: Mid-Atlantic BioTherapeutics is headquartered in Doylestown, US.